Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)
Clinical trial NCT06272487 · COMPLETED
Trial details
- NCT number
- NCT06272487
- Sponsor
- Alnylam Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-02-29
- Primary completion
- 2025-06-19
- Enrollment
- 375
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.